Attruby is making fast inroads thanks to its edge over Pfizer’s established Vyndaqel, but will soon face competition from Alnylam.
BridgeBio’s Attruby has got off to a strong start in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, racking up better-than-expected sales in its first few months on the market.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.
In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.
Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.
